CancerNetwork speaks with Josh Ludwig on its latest podcast to discuss ScaleReady’s plans to make cell and gene therapy more practical and viable moving forward.
This week, CancerNetwork spoke with Josh Ludwig, global director of commercial operations at ScaleReady, about how this joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf, launched in January 2021, is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.
Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.